ACT Genomics, Asia's leading next-generation sequencing (NGS) precision oncology provider, has announced a groundbreaking partnership with mProbe Inc. to exclusively integrate the innovative OncoOmicsDX proteomics platform across major Asian markets. The collaboration, announced on March 6, 2025, marks a significant advancement in precision medicine by combining genomic and proteomic analyses for enhanced cancer care.
Advancing Cancer Care Through Multi-Omics Integration
The strategic partnership extends across Taiwan, Hong Kong, Macau, Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, introducing a comprehensive proteogenomics approach to cancer diagnosis and treatment. OncoOmicsDX employs sophisticated mass spectrometry technology and AI-driven analytics to identify protein biomarkers associated with cancer progression and treatment response.
"We are excited to partner with mProbe Inc. to deliver a new dimension in precision oncology," said Dr. Hua Chien Chen, CEO of ACT Genomics. "With OncoOmicsDX, healthcare providers gain a holistic view of cancer biology, allowing them to make data-driven decisions that can significantly improve patient care."
Enhanced Molecular Insights for Personalized Treatment
The integration of proteomics with existing genomic profiling capabilities provides oncologists with deeper insights into tumor biology, enabling more precise treatment selection. This comprehensive approach helps identify:
- Targeted therapy opportunities
- Potential drug resistance mechanisms
- Novel therapeutic targets
- Biomarkers for treatment response
Peter Chen, CEO of mProbe Inc., emphasized the significance of the collaboration: "This partnership underscores the critical role proteomics plays in understanding how tumor biology evolves. ACT Genomics' proven track record and extensive network in Asia make them an ideal partner to accelerate the adoption of OncoOmicsDX."
Clinical Implementation and Future Impact
The combined proteogenomics platform will enable clinicians to:
- Access comprehensive molecular profiling data
- Make more informed treatment decisions
- Monitor treatment response more effectively
- Identify new therapeutic strategies
This integrated approach represents a significant step forward in precision oncology, offering healthcare providers and patients across Asia access to more sophisticated diagnostic and treatment planning tools. The partnership demonstrates both companies' commitment to advancing cancer care through innovative technological solutions and data-driven approaches.
